Coherus BioSciences Inc (NAS:CHRS)
$ 1.735 -0.025 (-1.42%) Market Cap: 199.05 Mil Enterprise Value: 420.44 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at UBS Global Healthcare Conference Transcript

May 24, 2022 / 06:00PM GMT
Release Date Price: $7.67 (-4.01%)
Ashwani Verma

Good day, everybody, and welcome to UBS Global Healthcare Conference. Our next company presentation here is Coherus Biosciences. From the company, I have Chairman, President and CEO, Denny Lanfear; and Chief Commercial Officer, Paul Reider. Over to you, guys.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Thank you. Thank you, Ash, and thank you for the opportunity to speak again here at UBS in New York and see everyone in person. Let me first apprise you of the forward-looking statements. Just a quick overview.

Let me first apprise you the forward-looking statements and refer you to the company's SEC filings with respect to the various products, including YUSIMRY, CIMERLI and UDENYCA. Now I'll first talk a little bit about the strategy, and then we'll go on and talk a little bit about our approach to immunotherapy. And then my good friend, Paul will talk about the commercial execution, which is so important over the next 12 to 18 months for us and what we're going to have there.

So first, let me remind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot